Sangui Biotech International Stock Performance
| SGBI Stock | USD 0.0002 0.00 0.00% |
The entity has a beta of -0.1, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sangui Biotech are expected to decrease at a much lower rate. During the bear market, Sangui Biotech is likely to outperform the market. At this point, Sangui Biotech Inter has a negative expected return of -1.38%. Please make sure to validate Sangui Biotech's treynor ratio and rate of daily change , to decide if Sangui Biotech Inter performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sangui Biotech International has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
| Begin Period Cash Flow | 29.8 K |
Sangui |
Sangui Biotech Relative Risk vs. Return Landscape
If you would invest 0.15 in Sangui Biotech International on December 26, 2024 and sell it today you would lose (0.13) from holding Sangui Biotech International or give up 86.67% of portfolio value over 90 days. Sangui Biotech International is currently does not generate positive expected returns and assumes 10.919% risk (volatility on return distribution) over the 90 days horizon. In different words, 97% of pink sheets are less volatile than Sangui, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sangui Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sangui Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Sangui Biotech International, and traders can use it to determine the average amount a Sangui Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SGBI |
Estimated Market Risk
| 10.92 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sangui Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sangui Biotech by adding Sangui Biotech to a well-diversified portfolio.
Sangui Biotech Fundamentals Growth
Sangui Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Sangui Biotech, and Sangui Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sangui Pink Sheet performance.
| Return On Asset | -0.64 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.50) % | |||
| Current Valuation | 1.68 M | |||
| Shares Outstanding | 209.9 M | |||
| Price To Earning | (18.33) X | |||
| Price To Book | 46.44 X | |||
| Price To Sales | 10.09 X | |||
| Revenue | 69.19 K | |||
| EBITDA | (18.44 K) | |||
| Cash And Equivalents | 30.47 K | |||
| Total Debt | 48.9 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (140.46 K) | |||
| Total Asset | 130.79 K | |||
| Retained Earnings | (37 M) | |||
About Sangui Biotech Performance
By evaluating Sangui Biotech's fundamental ratios, stakeholders can gain valuable insights into Sangui Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sangui Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sangui Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.Things to note about Sangui Biotech Inter performance evaluation
Checking the ongoing alerts about Sangui Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Sangui Biotech Inter help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sangui Biotech Inter generated a negative expected return over the last 90 days | |
| Sangui Biotech Inter has high historical volatility and very poor performance | |
| Sangui Biotech Inter has some characteristics of a very speculative penny stock | |
| Sangui Biotech International currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 69.19 K. Net Loss for the year was (63.34 K) with profit before overhead, payroll, taxes, and interest of 69.19 K. | |
| Sangui Biotech International currently holds about 30.47 K in cash with (140.46 K) of positive cash flow from operations. | |
| Roughly 13.0% of Sangui Biotech outstanding shares are owned by corporate insiders |
- Analyzing Sangui Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sangui Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Sangui Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sangui Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sangui Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sangui Biotech's pink sheet. These opinions can provide insight into Sangui Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sangui Pink Sheet analysis
When running Sangui Biotech's price analysis, check to measure Sangui Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangui Biotech is operating at the current time. Most of Sangui Biotech's value examination focuses on studying past and present price action to predict the probability of Sangui Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangui Biotech's price. Additionally, you may evaluate how the addition of Sangui Biotech to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |